We therefore administered IL-17A antibody twice weekly by intraperitoneal injection after ischemic insults (Figure 6A) and found that TLOs formation was abolished and renal fibrosis was attenuated (Figure 6B). This evidence concerns the gene IL17A and renal fibrosis.